539 results about "Docosahexaenoic acid" patented technology

A method for the treatment or prophylaxis of hypertriglyceridemia and hypercholesterolemia without concomitantly increasing LDL-serum cholesterol, in a human subject requiring such treatment, which method comprises orally administering to the patient an effective amount of a pharmaceutical composition in which the active ingredients comprise a mixture of fatty acids, wherein said mixture comprises at least about 60% by weight a combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from about 1.4:1 to about 5:1, wherein said combination is at least about 60% in the triglyceride form of the fatty acids and the balance is at least about 80% of mono and di-glycerides.

The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source. In some embodiments, the method comprises administering daily to the subject a dosage form comprising DHA ester substantially free of EPA, wherein the DHA ester is about 60% to about 99.5% (w/w) of the total fatty acid content of the dosage form. In some embodiments, the method comprises administering daily to the subject a dosage form comprising about 200 mg to about 4 g of DHA ester substantially free of EPA. In some embodiments, the foregoing methods also result in a lowering of the amount of total cholesterol in the subject.

Synthetic lipid composition in which the content and the distribution of the fatty acids are similar to those of human milk fat, containing less than 2% by weight of free fatty acids, in which palmitic acid is predominantly at the 2-position of the triacylglycerols and the arachidonic and docosahexaenoic acids are distributed between the 1-, 2- and 3-positions and in particular predominantly at the 2-position of the triacylglycerols.

Provided herein are systems and methods for producing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and/or derivatives and/or mixtures thereof by growing algae that produce the oils containing EPA and/or DHA and/or derivatives and/or mixtures thereof, harvesting the algae with fish in one or more enclosed systems, and then processing fish to separate and purify the EPA and/or DHA. The multi-trophic systems provided herein comprise at least one enclosure that contains the algae and the fishes, and means for controllably feeding the algae to the fishes. Also provided herein are the lipid compositions extracted from the fishes.

The use of macroalgal, microalgal, and fungally-derived materials provide, in combination with higher-plant derived materials, complete feeds for animal husbandry. The products and methods of the invention provide nutritional feed formulations, that reduce or eliminate the need for animal-derived materials. The feeds are useful for terrestrial or aquatic animals, and comprise docosahexaenoic acid and eicosapentaenoic acid.

The subject invention relates to isolated nucleic acid sequences or genes involved in polyketide synthase (PKS) biosynthetic pathways. In particular, such pathways are involved in the production of polyunsaturated fatty acids (PUFAs) such as, for example, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA). Specifically, the invention relates to isolating nucleic acid sequences encoding proteins involved in eukaryotic PUFA-PKS systems and to uses of these genes and encoded proteins in PUFA-PKS systems, in heterologous hosts, for the production of PUFAs such as EPA and DHA.

This invention is directed to a dietary regimen and a unique combination of nutritional supplements and a method. More specifically, this invention is directed to a unique combination of nutritional supplements which provides symptomatic relief from arthritis. The unique combination of nutritional supplements of this invention is believed to function by both increasing the available (effective blood level) of anti-inflammatory agents and promotion of the healing/regenerative process in the effected joints, thus, producing unexpected and lasting symptomatic relief from the debilitating effects of both osteoarthritis and rheumatoid arthritis. The essential nutritional supplements of the dietary regimen of this invention are as follows: (a) gamma linolenic acid (unrefined), hereinafter "GLA"(b) a mixture of eicosapentaenoic acid and docosahexaneoic acid, hereinafter collectively "EPA"(c) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, glucosamine sulfate and manganese aspartate, hereinafter collectively "CHONDROX"The regimen is adjusted based upon the weight of the individual, and once symptomatic relief is achieved, the individual remains essentially free from the debilitating effects of arthritis so as long the daily regimen is faithfully followed.

The invention relates to a method for enriching n-3 polyunsaturated fatty acid (n-3PUFA) from fish oil, which belongs to the food organism and functional health product technical field. The method takes the fish oil as a raw material, uses the chemical hydrolysis method to hydrolyze the fish oil, respectively obtains high-purity eicosapentaenoic acid (EPA) and high-purity docosahexaenoic acid (DHA) from the hydrolyzed fish oil through separation and purification, uses glycerol and the purified EPA or DHA as raw materials and utilizes lipase to respectively catalyze and synthesize an EPA glyceride product or a DHA glyceride product in an organic phase. The products are mainly n-3PUFA triglyceride; the purity of the products is high; and the concentration of EPA triglyceride in the EPA glyceride is between 90 and 95 percent, and the concentration of DHA triglyceride in the DHA glyceride is between 92 and 94 percent. The high-purity EPA triglyceride product and the high-purity DHA triglyceride product prepared by the method well improve the application pertinence of different health care efficacies of natural fish oil products and improve the functional health care value of the fish oil products.

The invention relates to an infant nutrition immunity formula powdered milk and a production method thereof, wherein, the production method of the infant nutrition immunity formula powdered milk comprises the following steps: milk which is raw material, is preprocessed, the mixed solution of docosahexaenoic acid and arachidonic acid is prepared, ingredients are mixed, preheating, homogenizing and heating are carried out for sterilizing, decompression is carried out for concentrating, and spray-drying under negative pressure and low temperature and drying on a fluidized bed are carried out, then cooling, packing and inspecting are carried out. The infant nutrition immunity formula powdered milk manufactured by the method of the invention mainly comprises casein phosphoeptide, vitamin D3, lactoferrin, nucleotide, linoleic acid, linolenic acid, the docosahexaenoic acid, the arachidonic acid, fructo-oligosaccharide and galacto-oligosaccharide, which has the advantage of reasonable trophic structure and also ensures that various nutrient substance to be absorbed and deposited to the utmost extend, so as to promote the development of brain and nervous system, improve active immunity, improve intestinal tract micro-ecological environment and strengthen the absorption of calcium, iron and zinc as well as effectively maintain every active nutrient component during the production process.

We describe a composition comprising a source of long chain polyunsaturated fatty acid, for example, docosahexaenoic acid (DHA), and a carotenoid, for example, astaxanthin and other nutrients for prophylactic and/or therapeutic use in the healing of trauma- and stress-induced inflammatory conditions.

The present disclosure provides formulations and methods for delivering water-soluble and lipid-soluble nutrients for preventing or correcting nutrient deficiencies to subjects requiring small-volume nutritional support, such as preterm infants. The formulations may comprise an emulsion of docosahexaenoic acid (DHA) stabilized by a protein emulsifier, such as α-lactalbumin, and may further comprise other valuable nutrients, such as arachidonic acid (ARA), arginine, glutamine, arginyl-glutamine dipeptide and/or alanyl-glutamine dipeptide. The formulation is useful, for example, for correcting nutritional deficiencies by increasing a subject's intake of nutrients such as ω-3 or ω-6 long-chain polyunsaturated acids, proteins, peptides, vitamins, minerals, other fatty acids, and/or essential amino acids. The nutritional formulation is suitable for enteral delivery and small-volume delivery via nasogastric tube, intragastric feeding, transpyloric administration and/or any other means of administration that result in the introduction of the nutritional formulation into the digestive tract of a subject.

The invention discloses infant formula goat milk powder added with structural grease and a preparation method thereof. The infant formula goat milk powder is prepared from the following components: 20 to 40 percent of lactose, 16 to 22 percent of edible vegetable oil, 3.2 to 9.6 percent of structural grease (1,3-dioleic acid and 2-palmitic acid triglyceride), 16 to 22 percent of concentrated goatwhey protein, 11 to 15 percent of degreased goat milk powder, 2 to 6 percent of glucose syrup solid, 1.0 to 1.5 percent of fructooligosaccharide, 0.5 to 1.0 percent of galactooligosaccharide, 0.15 to0.50 percent of arachidonic acid, 0.12 to 0.48 percent of docosahexaenoic acid, 0.6 to 1.2 percent of mineral premix, 0.08 to 0.12 percent of vitamin premix, and 0.01 to 0.05 percent of nucleotide. The invention also discloses the preparation method of the infant formula goat milk powder. According to the infant formula goat milk powder, the goat smell is effectively eliminated, growth and development of infants are promoted, absorption and utilization rate of calcium are improved, and bone toughness of the infants is promoted.

A dietary supplement system includes a dietary supplement composition for oral administration by an individual in the morning, the composition, including (a) a telomere maintenance complex including: Purslane extract (aerial parts); Turmeric rhizome extract (95% curcuminoids); Quercetin dehydrate, Cayenne pepper fruit; Vanadium (as vanadyl sulfate); Fenugreek seed; Astragalus root extract, Omega fatty acid complex including linoleic acid; alpha-linolenic acid; oleic acid borage seed oil gamma-linolenic acid), evening primrose oil fish body oil (eicosapentaenoic acid; docosahexaenoic acid); (b) a calorie restriction mimetics and gene expression complex including Trans-resveratrol (from Polygonum cuspidatum root extract); Pterostilbene Fisetin 50% (Buxus microphlla Sieb (stem and leaf; Alpha lipoic acid, Coenzyme Q-10, Betaine HCl, Sulfur (from methylsulfonylmethane); L-Carnitine tartrate; L-Carnitine HCl, and (c) a free radical scavenger complex, including Green tea leaf extract catechin and polyphenols); Anthocyanins (from bilberry fruit and grape skin extracts).

This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia.

Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day.

The present invention relates to Pseudomonas sp. YS-180 having a capability of producing a docosahexaenoic acid and a method for the production of DHA using such a microorganism. Pseudomonas sp. YS-180 was isolated and identified from the intestine of fishes by investigating the morphological, culturing, and physiological characteristics of a strain excellent in a DHA-producing capability. By TLC and GC, Pseudomonas sp. YS-180 according to the present invention was confirmed that it produced the greatest amount of DHA when it was shaking-cultured in a culture containing glucose 2% (w/v), a yeast extract 2% (w/v), and sea water 20%(v/v). Optimal conditions for producing DHA were a pH of 6.0, and a temperature of 20° C. Under these conditions a DHA production was 96.7 mg/L, and a biomass growth was 7.8 g/L.

The invention provides an infant milk powder with adjusted structure of aliphatic acid, which comprises the following raw materials (by weight portion in tons): dry matter of fresh milk 276, desalinized whey powder 450, structured fatty oil 105, lactose 50, fructooligosaccharide 20, alpha-lactalbumin 10, docosahexaenoic acid 5, arachidonic acid 6, nucleic acid 0. 42, taurine 0. 45, choline 0. 42, L-carnitine 0. 06, beta-carotene 0. 012, composite vitamin 2. 5, composite microelement 3. 5 and balancing refined vegetable oil.

A high quality nutritional composition for patients undergoing chemotherapy or radiation therapy or suffering chronic medical conditions comprises in combination: (A) Macronutrients comprising: (1) fat (2) protein (3) high quality carbohydrate and (B) micronutrients comprising (1) essential vitamins and minerals (2) Omega 3 DHA (docosahexaenoic acid) and (3) FOS (fructooligosaccharides).

The invention discloses a lutein ester health care product for protecting eyesight. The lutein ester health care product is prepared by taking lutein ester as a main material, and adding any one or more materials including taurine, selenium, zinc, alpha-lipoic acid, docosahexaenoic acid (DHA), vitamin A, vitamin E, vitamin B1, vitamin B2 and bilberry extract, and pharmaceutically acceptable formulation accessories. The outstanding innovation of the invention is the implementation of the method for preparing a functional eye health care product with the lutein ester instead of lutein, so that the bioavailability, the stability and the health care effect of the product are improved, and production cost can be greatly reduced. The health care product can be prepared into common dosage forms, such as tablets, capsula, granules and soft capsules. The lutein ester health care product is mainly used for the treatment on diseases, such as myopia, amblyopia, hyperopia, presbyopia, cataract, vitreous opacity, retinal pigment degeneration, macular degeneration, asthenopia, and retinopathy caused by diabetes, and the like. The lutein ester health care product adopts a unique formulation of multiple constituents, measures and mechanisms, and has significant treatment effects and excellent social and economic benefits.

The disclosure relates to an animal feed or feed ingredient containing from about 0.01% to 1.0% DHA, wherein all, or substantially all of the DHA comes from material that is of non-animal origin and the use of microbially-derived DHA at these low levels provides sufficient DHA for the optimal neurological development of the animal.

The invention relates to a method for preparing glyceride rich in algal oil n-3 polyunsaturated fatty acid through the enzyme process. The method comprises the following steps: taking microbial algal oil as raw material, carrying out hydrolysis of part or all of algal oil respectively through controlling the hydrolysis rate under the catalysis of lipases to obtain glyceride partially hydrolyzed and free fatty acid; enabling the free fatty acid to enrich n-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) through the urea adduct method to obtain an n-3 polyunsaturated fatty acid condensate; and taking the n-3 polyunsaturated fatty acid condensate and glyceride partially hydrolyzed as substrates, taking immobilized lipases as catalysts, and efficiently synthetizing glyceride rich in algal oil n-3 polyunsaturated fatty acid in an organic phase. The invention adopts a complete biological enzymatic enrichment process, the raw material is clean and safe, the process route is scientific and reasonable, the catalytic activity of enzyme is high, the catalyst can be recycled, the cost is low, the reaction condition is mild, the energy consumption is low, the environment is friendly, and the market prospect is wide.

The present disclosure relates to milk-based nutritional compositions for pediatric subjects and to corresponding methods of using the nutritional compositions to promote health and development. The nutritional compositions comprise docosahexaenoic acid, choline and phytonutrients, such as apple extract, grape seed extract, or mixtures thereof. The nutritional compositions are believed to be useful in promoting visual health, gastrointestinal health, immune function and cognitive development and function in infants and children, and the compositions may be administered via a staged nutritional feeding regimen. The disclosure further relates to nutritional compositions that maintain desirable organoleptic properties after addition of phytonutrients to a milk-based matrix and still further relates to methods for producing the same.

The invention relates to a method for extracting ethyl ester enriched fish oil from a fish oil refining byproduct, which comprises the following steps: by taking soapstock and solid lipid of the fish oil refining byproduct as raw materials, recovering the soapstock through an acid-based ethyl ester catalysis process, recovering the solid lipid through an alkali-based ethyl ester catalysis process, performing a secondary three-stage molecular distillation and primary urea inclusion combined process, and enriching to obtain the ethyl ester fish oil having high EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) content. According to the invention, the process is simple and low in cost, solves the byproduct recovery problem during fish oil refining, avoids environmental pollution, changes the wastes into valuable substances, and greatly increases the value of the product; and the physical and chemical indices of the extracted ethyl ester fish oil product conform to the standard, the fish oil has no rancid flavor, the total content of EPA and DHA is respectively increased to 78.42% and 76.15%, and the fish oil achieves better economic benefits.